Skip to content

EyePoint, Inc. EYPT Cash & Equivalents

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$666.7M+90.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$169.53M+22.1%
HRO
HarrowHROW
$94.64M+41.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$175M+37.8%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's cash & equivalents?
EyePoint, Inc. (EYPT) reported cash & equivalents of $77.71M in Q1 2026.
How has EyePoint, Inc. 's cash & equivalents changed year-over-year?
EyePoint, Inc. 's cash & equivalents decreased by 8.7% year-over-year, from $85.16M to $77.71M.
What is the long-term trend for EyePoint, Inc. 's cash & equivalents?
Over 5 years (2020 to 2025), EyePoint, Inc. 's cash & equivalents has grown at a 17.8% compound annual growth rate (CAGR), from $44.91M to $101.82M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.